Cargando…
AB005. Treatment of Peyronie’s disease: 2016 updates
The approval of Xiaflex (collagenase clostridium histolyticum) by the FDA in the US in December of 2013 has significantly changed the management of Peyronie’s disease. Based on author’s experience in treating the disease for more than 25 years and giving more than 1,000 Xiaflex injections, a refined...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4842559/ http://dx.doi.org/10.21037/tau.2016.s005 |